Källén Bengt A J, Olausson Petra Otterblad
Tornblad Institute, University of Lund, Lund, Sweden.
Am J Obstet Gynecol. 2006 Feb;194(2):480-5. doi: 10.1016/j.ajog.2005.06.087.
The purpose of this study was to evaluate delivery outcome after maternal use of oral decongestants.
We identified 2474 women who had reported the use of oral decongestants (mainly phenylpropanolamine) during early pregnancy and 1771 women who used prescription oral decongestants later in pregnancy. With Mantel-Haenszel analysis, comparisons were made with all women who gave birth in Sweden.
The risk ratio for any congenital malformation after the use of oral decongestants was 0.96 (95% CI, 0.80-1.16). Women who were prescribed decongestants after the first antenatal visit less often than expected had infants who were born preterm (odds ratio, 0.68; 95% CI, 0.52-0.88), of low birth weight (odds ratio, 0.53; 95% CI, 0.37-0.77), small-for-date (odds ratio, 0.71; 95% CI, 0.47-1.08), or perinatally dead (odds ratio, 0.53; 95% CI, 0.22-12.5).
No teratogenic effect of oral decongestants was found. An association found between the late pregnancy use of such drugs and a favorable neonatal outcome can be explained hypothetically by the postulated association between pregnancy rhinitis and placental hormones.
本研究旨在评估孕妇使用口服减充血剂后的分娩结局。
我们确定了2474名在孕早期报告使用口服减充血剂(主要为苯丙醇胺)的女性以及1771名在孕晚期使用处方口服减充血剂的女性。采用Mantel-Haenszel分析方法,与在瑞典分娩的所有女性进行比较。
使用口服减充血剂后出现任何先天性畸形的风险比为0.96(95%可信区间,0.80 - 1.16)。首次产前检查后开具减充血剂处方的女性,其婴儿早产(比值比,0.68;95%可信区间,0.52 - 0.88)、低出生体重(比值比,0.53;95%可信区间,0.37 - 0.77)、小于胎龄(比值比,0.71;95%可信区间,0.47 - 1.08)或围产期死亡(比值比,0.53;95%可信区间,0.22 - 12.5)的情况比预期少。
未发现口服减充血剂有致畸作用。孕期晚期使用此类药物与良好的新生儿结局之间的关联可以通过妊娠鼻炎与胎盘激素之间的假定关联进行假设性解释。